Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
NA ixazomib Ninlaro 4 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Prednisolone Tebutate Hydeltra-TBA, Norpred TBA, Predalone T.B.A., Predate TBA, Predcor TBA, Prednisol TBA, Prednisolone TBA, TBA Pred 20 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1956 2003 In Use
NA Ruxolitinib Jakafi 5 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Ruxolitinib Jakafi 15 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Altretamine Hexalen 50 mg Chemotherapy Alkylating Agent Triazines Yes 1990 2019 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Erlotinib Tarceva 150 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Fluoxymesterone Androxy 10 mg Hormonal Therapy Androgen Yes 1983 In Use
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Bexarotene Targretin 75mg Chemotherapy Immunomodulator Retinoic Acid Derivative Yes 2014 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.